Zealand Pharma Price to Book Ratio 2017-2021 | ZEAL

Historical price to book ratio values for Zealand Pharma (ZEAL) over the last 10 years. The current price to book ratio for Zealand Pharma as of October 22, 2021 is 6.25.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Zealand Pharma Price/Book Ratio Historical Data
Date Stock Price Book Value per Share Price to Book Ratio
2021-10-22 32.28 6.25
2021-06-30 29.36 $5.16 5.69
2021-03-31 31.96 $6.21 5.15
2020-12-31 35.94 $4.73 7.60
2020-09-30 38.41 $6.28 6.12
2020-06-30 35.00 $6.69 5.23
2020-03-31 34.50 $4.87 7.09
2019-12-31 33.20 $5.17 6.43
2019-09-30 25.36 $5.85 4.33
2019-06-30 21.52 $4.58 4.70
2019-03-31 17.02 $5.21 3.27
2018-12-31 11.61 $5.49 2.12
2018-09-30 16.52 $6.29 2.63
2018-06-30 12.68 $1.65 7.70
2018-03-31 15.02 $2.35 6.40
2017-12-31 13.60 $2.61 5.21
2017-09-30 19.20 $3.28 5.85
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.407B $0.054B
Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76